Adjuvanted vaccine boosts flu protection for elderly

by Camilo Mejia Giraldo
Researchers analysed a demographic that has increasing issues with their immune system’s response to vaccines. Credit: BromfordGroup

A recent study has strengthened the current knowledge of the increased effectiveness of adjuvanted flu vaccines in the elderly—a population highly affected by seasonal influenza.

Adjuvants are substances that can be added to vaccines to aid the body's immune response to the .

The 'real world' study, based in Canada, assessed less than 300 elderly for adjuvanted .

It found an MF59 adjuvanted vaccine provided more protection (60 per cent effectiveness) against compared with the unadjuvanted trivalent influenza vaccine.

"We've seen data before that said if you just measure [the patient's] blood anti-body levels, it shows that they do better with the adjuvanted [vaccines]," says Dr Paul Van Buynder, a UWA appointee and co-author of the study.

"What we weren't sure of was whether that would turn into better protection against actual flu, and that is what we were looking at," he says.

Researchers contacted people over 65 years-old who had been routinely lab tested after they had exhibited influenza-like symptoms.

"We have different polices in different parts of British Columbia, some clinics give the adjuvanted vaccines and some do not, so the study was a natural experiment," he says.

After the participants were interviewed, their vaccination status, date and type were confirmed through healthcare records.

Dr Van Buynder says even though adjuvanted vaccines are known to have superior effects, researchers of the study were pleased at the positive results showed by MF59—which is a oil-in-water adjuvant containing a shark oil derivative and two surfactants.

With participants of the study at a median age of 83 years, researchers analysed a demographic that has increasing issues with their immune system's response to vaccines.

"It's a thing called immunosenescence, the older you get, the worse your white cells produce anti-bodies," he says.

"This is a new generation of adjuvants … it actually has an impact on stimulating the antigen production cells, particularly the dendritic cells in the skin area, so they bring a lot more antibodies across to where the vaccine has been administered."

Dr Van Buynder says adjuvanted vaccines are widely used throughout Canada and the EU, but not in the United States or Australia—although some adjuvanted vaccines are licensed in Australia.

"We were looking at what whether in the real world it actually made a difference," he says.

"Because it's one thing to look at the blood levels in a lab and what we wanted to say is that this actually produces a difference."

More information: www.sciencedirect.com/science/… ii/S0264410X13010451

Related Stories

New development could increase flu vaccine supply

date Jun 02, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or com ...

Young children respond well to recommended swine flu vaccine

date May 28, 2010

The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with ...

Recommended for you

Score IDs patients with upper extremity DVT at low risk

date 5 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

date 15 hours ago

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date 15 hours ago

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.